Lonza is selling its capsules and health ingredients business to the British private equity firm Lone Star Funds. The deal, worth CHF2.3 billion ($3 billion), is expected to be completed in the second half of 2026. +Get the most important news from Switzerland in your inbox Lonza will receive CHF1.7 billion in cash immediately and will retain a 40% stake in its capsules and health ingredients (CHI) business, with a preferential right on any future sale, the Basel-based pharma supplier said in a press release on Wednesday. Lonza plans to use the CHF1.7 billion to finance organic growth, make targeted acquisitions and strengthen its technological and industrial capacities in contract development and manufacturing organisation (CDMO), the statement said. In addition, CHF500 million will be redistributed to shareholders through a share buyback programme once the initial payment has been received. The total gain from the sale of the CHI division, including the initial product and all ...
